Shots: The P-III SOLO-1 Trial includes assessing of Lynparza (olaparib) (300mg bid) vs PBO in 391 patients in ratio (2:1) with newly-diagnosed, BRCA1/2 mutation who were in CR or PR […]readmore
Tags : Lynparza (olaparib)
Shots: The Fourth ODD is based on the ongoing P-III POLO study assessing Lynparza (300mg bid) as monotherapy vs PBO in ratio (3:2) & 1EP as PFS in 145 patients […]readmore